Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712507 | 1.00 | AOC3 (0.54) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL29631691 | 0.74 | RAB9A (0.74) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL374022 | 0.74 | RAB9A (0.74) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL10481645 | 0.73 | DAO (0.60) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL29377234 | 0.72 | AOC3 (0.56) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL665958 | 0.70 | AOC3 (0.54) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL1388385 | 0.70 | AOC3 (0.54) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL274332 | 0.70 | FLT3 (0.59) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL980499 | 0.70 | AOC3 (0.54) | AOC3NPC1RAB9ALOXL2FLT3 | |
| SCHEMBL7644722 | 0.70 | AOC3 (0.54) | AOC3NPC1RAB9ALOXL2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 665 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269072-A1 | PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES | CENTENARY INST OF CANCER MEDICINE AND CELL BIOLOGY (AU) | 2025-08-28 | — | — | US | claimed |
| US-12283647-B2 | Chelating agents for quantum dot precursor materials in color conversion layers for micro-LEDs | APPLIED MATERIALS, INC. (US) | 2025-04-22 | — | — | US | claimed |
| US-12129437-B2 | Method for the dissolution of amorphous dithiazines | CONOCOPHILLIPS COMPANY (US) | 2024-10-29 | — | — | US | claimed |
| EP-4416121-A1 | PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES | Centenary Institute Of Cancer Medicine And Cell Biology (AU) | 2024-08-21 | — | — | EP | claimed |
| US-20240194836-A1 | CHELATING AGENTS FOR QUANTUM DOT PRECURSOR MATERIALS IN COLOR CONVERSION LAYERS FOR MICRO-LEDS | APPLIED MATERIALS, INC. | 2024-06-13 | — | — | US | claimed |
| US-11908979-B2 | Chelating agents for quantum dot precursor materials in color conversion layers for micro-LEDs | APPLIED MATERIALS, INC. (US) | 2024-02-20 | — | — | US | claimed |
| US-11888096-B2 | Quantum dot formulations with thiol-based crosslinkers for UV-LED curing | APPLIED MATERIALS, INC. (US) | 2024-01-30 | — | — | US | claimed |
| US-11814588-B2 | Elemental sulfur dissolution and solvation | CONOCOPHILLIPS COMPANY (US) | 2023-11-14 | — | — | US | claimed |
| EP-4225511-A1 | METHOD FOR THE DISSOLUTION OF AMORPHOUS DITHIAZINES | Conocophillips Company (US) | 2023-08-16 | — | — | EP | claimed |
| EP-4225973-A1 | ELEMENTAL SULFUR DISSOLUTION AND SOLVATION | Conocophillips Company (US) | 2023-08-16 | — | — | EP | claimed |
| EP-0264198-B1 | OPTICAL INFORMATION RECORDING MEDIUM | CANON KABUSHIKI KAISHA (JP) | 1993-03-03 | — | — | EP | claimed |
| US-5190846-A | Storage stability, high releasing speed, sharp image, contrast | FUJI PHOTO FILM CO., LTD. (JP) | 1993-03-02 | — | — | US | claimed |
| US-5178995-A | Reflectance, storage stability | CANON KABUSHIKI KAISHA (JP) | 1993-01-12 | — | — | US | claimed |
| US-5155004-A | Chitosan or chitin derivative and method for processing silver halide photographic material by using the same | FUJI PHOTO FILM CO., LTD. (JP) | 1992-10-13 | — | — | US | claimed |
| EP-0403100-A2 | High sensitivity photopolymerizable compositions containing hydrogen donating mercaptans | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-12-19 | — | — | EP | claimed |
| US-4950764-A | HERBICIDES, BACTERICIDES, ANALGESICS, ANTIINFLAMMATORY AGENT | FUJI PHOTO FILM CO., LTD. (JP) | 1990-08-21 | — | — | US | claimed |
| US-4939066-A | DEVELOPMENT INHIBITOR-RELEASING COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1990-07-03 | — | — | US | claimed |
| US-4824759-A | CYCLIZATION OF A 2-MERCAPTOBENZAZOLE RING | FUJI PHOTO FILM CO., LTD. (JP) | 1989-04-25 | — | — | US | claimed |
| EP-0264198-A2 | Optical information recording medium | CANON KABUSHIKI KAISHA (JP) | 1988-04-20 | — | — | EP | claimed |
| US-4636456-A | EXPOSURE, SILVER HALIDE EMULSIONS, HYDROQUINONE OR ESTER OR CARBONATE, DEVELOPMENT INHIBITORS | FUJI PHOTO FILM CO., LTD. (JP) | 1987-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269072-A1 | PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES | AS3MT, TP53, ANXA5 | AOC3 2448/4885NPC1 3304/4885RAB9A 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.